UK Markets close in 7 hrs 40 mins

AstraZeneca PLC (AZN.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
5,239.1626+30.16 (+0.35%)
At close: 5:06PM BST
Interactive chart
Previous close5,209.0000
Bid5,150.0000 x 6100
Ask5,295.0000 x 13000
Day's range5,212.0000 - 5,288.9805
52-week range3,680.0000 - 5,505.0000
Avg. volume2,337,777
Market cap66.31B
PE ratio (TTM)19.62
Earnings dateN/A
Dividend & yield2.80 (4.23%)
Ex-dividend date2017-02-16
1y target estN/A
  • American City Business Journals14 hours ago

    AstraZeneca recalls physician sample bottles of heart drug

    AstraZeneca is voluntarily recalling one lot of physician sample bottles of Brilinta — a blood-thinning drug prescribed to prevent stroke, heart attack and other heart problems — as a precautionary measure. The London-based pharmaceutical company, which has its U.S. headquarters in Wilmington, said the voluntary recall follows a report that a professional sample bottle containing eight, 90 milligram tablets of Brilinta also contained another medicine, Zurampic tablets, also manufactured by AstraZeneca (AZN).

  • 3 Top Dividend Stocks in Cancer Drugs
    Motley Fool17 hours ago

    3 Top Dividend Stocks in Cancer Drugs

    There are lot of companies focusing on cancer drugs that pay dividends. AbbVie, AstraZeneca, and Pfizer stand at the top of the list.

  • Reuters - UK Focus4 days ago

    Drug approvals bounce back as R&D labs churn out new winners

    The U.S. Food and Drug Administration has already cleared 21 new prescription medicines for sale against 22 in the whole of 2016, and just nine at this stage last year. The European Medicines Agency has recommended 42 compared with a 2016 total of 81, and 31 in the first five months of last year. Unlike the FDA, the EMA includes generic or non-patented drugs in its list.